Search Bar & Filters
Found 101 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.
Actively Recruiting
Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.
Actively Recruiting
Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of CS-1103, a drug given by intravenous infusion, in healthy adults aged 18 to 55. The study specifically looks at how CS-1103 behaves when administered after a clinically relevant dose of fentanyl, with naloxone used to block fentanyls effects. This phase 2 trial aims to understand CS-1103s effects in the presence of fentanyl overdose conditions. Participants are randomly assigned to one of two groups. One group receives an intravenous naloxone blockade, followed by fentanyl, and then placebo saline. The other group receives the same naloxone and fentanyl doses, followed by a single intravenous dose of CS-1103 at 1,000 mg. The study uses a quadruple-blind design, meaning participants, care providers, investigators, and outcomes assessors do not know who receives which treatment. During the study, participants are monitored closely for adverse events through physical exams, electrocardiograms, vital signs, and laboratory tests over 3 days plus a follow-up on day 10. Blood and urine samples are collected to measure CS-1103 and fentanyl concentrations over 48 hours. Researchers also assess effects on heart rhythm intervals and naloxone levels. The study involves healthy volunteers with prior opioid experience and includes detailed safety and pharmacokinetic evaluations.
Actively Recruiting
Researchers are evaluating a new eye drop containing pregabalin TB0001 as a potential treatment for adults with primary open-angle glaucoma or ocular hypertension. The study aims to compare how well TB0001 lowers eye pressure to timolol, a commonly used glaucoma eye drop, while checking safety and tolerability. This is a phase 2a randomized trial to identify the best dose of TB0001 for future studies. Participants will be randomly assigned to receive one of three strengths of TB0001 0.9%, 1.2%, or 1.5% once daily in the morning along with a matching placebo drop in the evening, or timolol 0.5% eye drops twice daily morning and evening. The treatment period lasts 28 days with both active and placebo drops used to keep the study masked. This double-masked, double-dummy design ensures fair comparison among groups. During the study, participants will have their eye pressure measured at several time points including baseline and day 28 to assess changes. Eye health, side effects, and tolerability will be monitored throughout. Additional assessments occur on days 1, 3, 7, and 14. Researchers will track the proportion of participants achieving significant eye pressure reduction and record any adverse events. The total participation is about one month.
Actively Recruiting
Researchers are studying the safety and effectiveness of intravitreal KSI-101 injections in adults with macular edema caused by inflammation, called Macular Edema Secondary to Inflammation MESI. This Phase 3 clinical trial aims to evaluate how well KSI-101 works compared to a sham injection in improving vision for people with this condition. Participants will receive one of three treatments KSI-101 at 5 mg or 10 mg doses injected into the eye every 4 weeks for six months, followed by dosing tailored to individual needs, or a sham injection following the same schedule. The study is randomized, double-masked, and controlled to ensure unbiased results. During the trial, participants will undergo vision tests to measure changes in best-corrected visual acuity BCVA over 24 weeks. Researchers will monitor safety and treatment effects throughout the study. The trial is expected to run until November 2027, with participants receiving regular assessments and follow-ups to track their eye health and response to treatment.
Actively Recruiting
Researchers are conducting a Phase 3 clinical trial to evaluate the safety and effectiveness of intravitreal KSI-101 in adults with macular edema caused by inflammation, known as Macular Edema Secondary to Inflammation MESI. The study aims to understand how well this treatment works compared to a sham injection in improving vision and reducing eye swelling related to this condition. Participants are randomly assigned to receive one of three treatments an intravitreal injection of KSI-101 at either 5 mg or 10 mg doses once every four weeks for six months, followed by personalized dosing schedules, or a sham injection on the same schedule. The injections are given directly into the eye, and the study is double-masked to ensure unbiased results. During the study, participants will undergo regular eye exams to measure visual acuity and eye thickness using specialized imaging. The main outcome is the change in best corrected visual acuity at 24 weeks. Researchers will also monitor the proportion of participants who show improvement in vision over this period. The trial includes safety assessments and will continue until August 2027, with detailed monitoring throughout the treatment and follow-up phases.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating the effects of BGE-102 on vision changes in adults with center-involved diabetic macular edema CI-DME. This phase 2 study aims to assess how BGE-102, alone or combined with an anti-vascular endothelial growth factor anti-VEGF drug, affects ocular health and vision over a 12-week treatment period. The study also monitors the safety and tolerability of BGE-102. Participants will be randomly assigned to one of three groups BGE-102 capsules taken once daily combined with sham injections, BGE-102 capsules combined with anti-VEGF injections every four weeks, or placebo capsules combined with anti-VEGF injections every four weeks. The total treatment lasts up to 12 weeks. The study includes a screening period up to 4 weeks and a 4-week follow-up after treatment ends. During the approximately 20-week study, participants attend visits every two weeks for the first month of treatment, then every four weeks until week 16. Researchers will evaluate vision using best corrected visual acuity at week 12 as the main outcome. Safety is also carefully monitored through adverse event tracking up to week 16. Participants may undergo eye charts, retinal scans, and other ocular assessments throughout the study.
1-10 of 101
1